Lifeline Scientific, Inc RESULTS OF SPECIAL MEETING (9227L)
October 06 2016 - 10:18AM
UK Regulatory
TIDMLSIC
RNS Number : 9227L
Lifeline Scientific, Inc
06 October 2016
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN
PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION
WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR
REGULATIONS OF SUCH JURISDICTION
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION
Lifeline Scientific, Inc.
("LSI" or the "Company")
RESULTS OF SPECIAL MEETING
Lifeline Scientific, Inc. (AIM: LSIC), a leading international
provider of clinical products and services in the field of
transplantation, announces that at the special meeting of LSI's
stockholders held today at 9.00 a.m. local time (US CDT) all
resolutions were duly passed and approved. This included
resolutions to:
1. adopt the agreement and plan of merger entered into with
Shanghai Genext Medical Technology Co., Ltd. and certain of its
affiliates (the "Merger Agreement" and the transaction provided for
therein, the "Merger"); and
2. approve the cancellation of the admission of LSI's common
stock to trading on the AIM market of the London Stock Exchange plc
("AIM") conditional on closing of the Merger (the
"Cancellation").
The closing of the Merger is still subject to regulatory review
and certain other customary closing conditions as provided for in
the Merger Agreement. At least twenty business days prior to the
effective time of the Merger, the Company intends to make an
application to the London Stock Exchange plc for the Cancellation
to take effect from 7.00 a.m. (UK time) on the next business day
after the date of the effective time of the Merger. It is currently
expected that closing will occur no later than 9 December 2016
(subject to extension under certain circumstances).
LSI will announce further details of the Cancellation timetable
in due course. It is expected that the last day of dealing in LSI's
common stock prior to their cancellation from trading on AIM and
the last day for registration of transfers of LSI's common stock
will be the date of the effective time of the Merger. No transfers
of LSI's common stock will be registered after that time and date.
All of LSI's shares of common stock and the depositary interests
representing such common stock held in CREST will be cancelled with
effect from the effective time of the Merger.
For further information:
Lifeline Scientific, Inc. www.lifeline-scientific.com
David Kravitz, CEO Tel: +1 847 294 0300
Lisa Kieres, CFO Tel: +1 847 294 0300
Piper Jaffray Ltd. (Financial Tel: +44 (0)20 7796 8400
Adviser to LSI)
Neil Mackison / Graeme Smethurst
Panmure Gordon (UK) Limited Tel: +44 (0)20 7886 2500
Freddy Crossley / Duncan Monteith (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or lifeline@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7584
391 303
About Lifeline Scientific Inc.
Lifeline Scientific, Inc. is a Chicago-based global medical
technology company with regional offices in Brussels and Sao Paulo.
The Company's focus is the development of innovative products that
improve transplant outcomes and lower the overall costs of
transplantation. Its lead product, LifePort Kidney Transporter, is
the global market-leading medical device for hypothermic machine
preservation of donor kidneys. LifePorts and novel solutions
designed for preservation of other organs are in development, with
LifePort Liver Transporter next in line for commercial launch. For
more information please visit www.lifeline-scientific.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCZQLFBQBFFFBD
(END) Dow Jones Newswires
October 06, 2016 10:18 ET (14:18 GMT)
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
From Apr 2024 to May 2024
Lifeline Sci (LSE:LSIC)
Historical Stock Chart
From May 2023 to May 2024